Lexeo Therapeutics, Inc. filings document a clinical-stage cardiovascular genetic medicine company and its formal disclosures on operations, pipeline progress, governance, and capital resources. Recent 8-K reports furnish financial results, business highlights, corporate presentations, and clinical updates for AAV gene therapy programs including LX2006 and LX2020.
The company’s SEC record also covers Regulation FD materials, CMC and regulatory-update disclosures, leadership transitions, director appointments, compensatory arrangements, and proxy matters for annual stockholder meetings. Its definitive proxy statement addresses board service, committee structure, voting proposals, executive compensation, and other governance information relevant to Lexeo’s public-company oversight.
Lexeo Therapeutics announced a planned CFO transition: Louis Tamayo will become Chief Financial Officer effective August 15, 2025, succeeding Dr. Kyle Rasbach, who will provide transition support through August 29, 2025. Mr. Tamayo joins with senior finance experience at Siemens Healthineers, Becton Dickinson and Pfizer.
Mr. Tamayo's initial compensation includes a $480,000 base salary, a discretionary target cash bonus equal to 40% of base salary, 45,000 RSUs and options to purchase 280,000 shares with standard multi-year vesting. Termination protections provide a lump-sum payment equal to 12 months' base salary and up to 12 months of COBRA reimbursement; enhanced change-in-control provisions add a year’s target bonus, COBRA and equity acceleration. Dr. Rasbach will receive a $128,000 lump sum and accelerated vesting of 40,466 options, and his resignation was stated to not result from any disagreement with the company.
Balyasny Asset Management and related entities reported beneficial ownership of 8,345,651 shares of Lexeo Therapeutics common stock, representing approximately 9.99% of the outstanding shares based on the issuer's reported share count. The position includes 4,336,514 shares issuable upon exercise of warrants, and the filing states the warrants cannot be exercised to the extent they would cause the holders to beneficially own more than 9.99% (a 9.99% blocker).
The filing explains that the reported shares are held through an investment client (Atlas Diversified Master Fund, Ltd.) for which Balyasny serves as investment manager, and that the Reporting Persons have sole voting and dispositive power over the reported shares. The Reporting Persons certified the holdings were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control.